King Buys Aventis’ Synercid, Tilade, Intal; Will Add 85 Reps To Sales Force

A potential Synercid indication in methicillin-resistant Staphylococcus aureus is one milestone trigger in King's agreement to purchase rights to the antibiotic and two asthma drugs from Aventis

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet